Separation and quantification of monoclonal-antibody aggregates by hollow-fiber-flow field-flow fractionation

被引:0
作者
Jun Fukuda
Takafumi Iwura
Shigehiro Yanagihara
Kenji Kano
机构
[1] Kyoto University,Graduate School of Agriculture
[2] Kyowa Hakko Kirin Co.,Bio Process Research and Development Laboratories, Production Division
[3] Ltd.,undefined
来源
Analytical and Bioanalytical Chemistry | 2014年 / 406卷
关键词
Antibodies aggregates; Hollow-fiber-flow field-flow fractionation; Size-exclusion chromatography; Analytical ultracentrifugation; Asymmetric-flow field-flow fractionation;
D O I
暂无
中图分类号
学科分类号
摘要
Hollow-fiber-flow field-flow fractionation (HF5) separates protein molecules on the basis of the difference in the diffusion coefficient, and can evaluate the aggregation ratio of proteins. However, HF5 is still a minor technique because information on the separation conditions is limited. We examined in detail the effect of different settings, including the main-flow rate, the cross-flow rate, the focus point, the injection amount, and the ionic strength of the mobile phase, on fractographic characteristics. On the basis of the results, we proposed optimized conditions of the HF5 method for quantification of monoclonal antibody in sample solutions. The HF5 method was qualified regarding the precision, accuracy, linearity of the main peak, and quantitation limit. In addition, the HF5 method was applied to non-heated Mab A and heat-induced-antibody-aggregate-containing samples to evaluate the aggregation ratio and the distribution extent. The separation performance was comparable with or better than that of conventional methods including analytical ultracentrifugation–sedimentation velocity and asymmetric-flow field-flow fractionation.
引用
收藏
页码:6257 / 6264
页数:7
相关论文
共 104 条
  • [1] Reichert JM(2008)undefined Curr Pharm Biotechnol 9 423-430
  • [2] Cromwell ME(2006)undefined AAPS J 8 E572-E579
  • [3] Hilario E(1999)undefined Int J Pharm 185 129-188
  • [4] Jacobson F(2013)undefined Trends Anal Chem 49 118-125
  • [5] Wang W(2012)undefined Biotechnol Prog 28 608-622
  • [6] Filipe V(2004)undefined Biopharm Int 17 22-26
  • [7] Hawe A(2006)undefined AAPS J 8 E501-E507
  • [8] Carpenter JF(2009)undefined J Pharm Sci 98 1202-1205
  • [9] Jiskoot W(2010)undefined J Pharm Sci 99 3302-3321
  • [10] Eon-Duval A(2000)undefined Biophys J 78 1606-1619